Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, discusses recent developments in immune-oncology research as well as promising avenues for the future of the field. Dr Balko continues by commenting on the recent SWOG S2206 trial which examined patients with high risk estrogen receptor positive (ER+) breast cancer and the possibility of identified biomarkers being used as companion diagnostics in the future. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.